The article discusses research being done on new oral therapy for childhood asthma. Consensus guidelines for treating moderate asthma are outlined elsewhere. The role of the other leukotriene inhibitors is not well defined in these guidelines. This 8-week study provides surrogate data that children may benefit from montelukast therapy. However, more pertinent patient-oriented outcomes were affected minimally, if at all. In addition, there are no direct comparisons with other more traditional therapies known to provide long-term control, such as inhaled corticosteroids or mast cell stabilizers.